Purpose

An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC) - Documentation of a pathogenic or likely pathogenic truncating variant in PKP2 - Frequent premature ventricular contractions (PVCs) - Patients must have an ICD placed prior to enrollment - Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.

Exclusion Criteria

  • Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy. - A history of other cardiac abnormalities as specified in the protocol. - New York Heart Association symptoms of heart failure of Class IV at the time of consent. - A history of prior gene transfer therapy.

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Case-Only
Time Perspective
Other

Recruiting Locations

Leland Stanford Junior University
Redwood City 5386834, California 5332921 94063-3126
Contact:
Priya Nair
512-217-3812
ashas@stanford.edu

Johns Hopkins University
Baltimore 4347778, Maryland 4361885 21287
Contact:
Crystal Tichnell
410-502-7161
ctichne1@jhmi.edu

Northshore University Healthsystem Research Institute
Columbia 4352053, Maryland 4361885 21044

University of Michigan
Ann Arbor 4984247, Michigan 5001836 48109
Contact:
Muhammad Hussain
734-765-8217
muhammhu@med.umich.edu

Henry Ford Hospital
Detroit 4990729, Michigan 5001836 48202

University of Rochester
Rochester 5134086, New York 5128638 14642

More Details

NCT ID
NCT06976606
Status
Recruiting
Sponsor
Lexeo Therapeutics

Study Contact

Person*: Lexeo Clinical Trials
212-547-9879
clinicaltrials@lexeotx.com

Detailed Description

SNAPSHOT-PKP2 is an observational, multicenter study that consists of 2 parts, a retrospective EMR review (up to 2 years) and a prospective observational study (1 year), to evaluate the clinical burden of illness of patients with PKP2-ACM, and to prospectively evaluate changes in key cardiac parameters and patient-reported outcome measures (PROMs) associated with PKP2-ACM progression.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.